No, as we have always understood Acadia can restrict 2591 development in new indications where they may commence trofinetide clinical development - refer sections 6.2 and 11.1 in particular.
An important question is what constitutes "commencement...of clinical development, of which ACADIA is the sponsor..." - this is not defined in the agreement.
No, as we have always understood Acadia can restrict 2591...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.52 |
Change
0.310(2.04%) |
Mkt cap ! $1.983B | |||
| Open | High | Low | Value | Volume |
| $15.19 | $15.62 | $15.11 | $8.655M | 558.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 440 | $15.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.54 | 752 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |